Novartis Zometa Picks Up 17% Of Company’s Bisphosphonate Business
Executive Summary
Novartis Zometa sales comprise 17% of the company's bisphosphonate business, Oncology President David Epstein said Feb. 7 in reviewing the company's efforts to switch patients from the company's older bisphosphonate oncologic Aredia